Business Wire

TA Associates Acquires Majority Interest in Masquepet S.L. (Kiwoko) from Corpfin Capital and Prince Capital Partners

Del

TA Associates, a leading global growth private equity firm, today announced that it has completed a majority investment in Masquepet S.L. (“Kiwoko”). Corpfin Capital Fund III (“Corpfin Capital”) and Prince Capital Partners, S.C.R., S.A. (“Prince Capital”) have exited their investment in Kiwoko, selling their 89.4% stake to TA Associates and the founders of Kiwoko. Financial terms of the transaction were not disclosed.

Founded in 2007 by Álvaro Gutiérrez, Javier Osa and Emilio Goyanes, and headquartered in Madrid, Kiwoko is the largest chain of pet care specialty retail stores in Spain. Over the last nine years, and with the financial support of Corpfin Capital and Prince Capital, the founders have grown Kiwoko to become Iberia’s sector leader with approximately 90 stores in Spain and Portugal.

Prince Capital and the founders provided Kiwoko with seed capital to start the business and, in February 2012, invited Corpfin Capital to provide the growth capital required to continue to grow the company. Since then, Kiwoko has successfully implemented an ambitious expansion plan that has resulted in the opening of 43 new stores and 40 vet clinics, the acquisition and integration of several smaller chains, including Mr. Guau and Zona Mascota, and the development of a full online business. During this period, Kiwoko generated approximately 700 new jobs and achieved more than 3,000 animal adoptions.

With TA Associates’ support, Kiwoko will seek to capitalize on significant growth opportunities in the Iberian pet care market.

“Kiwoko’s impressive expansion and notable business momentum is a perfect fit for TA’s growth-focused consumer investment strategy,” said Patrick Sader, a Director at TA Associates who will join Kiwoko’s Board of Directors. “We are delighted to partner with Álvaro and Javi to support Kiwoko in its next stage of organic and acquisitive growth.” Christopher Parkin, a Managing Director at TA Associates, will also join Kiwoko’s Board of Directors.

"It has been a privilege for Corpfin Capital to have the opportunity to partner with Prince Capital to support such an extraordinary team of entrepreneurs as Kiwoko’s founders,” said Álvaro Olivares, the Partner at Corpfin Capital responsible for Kiwoko. “TA Associates’ involvement will help Kiwoko rapidly develop to its full potential.”

"We are pleased to have supported Kiwoko through its start-up stage and to have partnered with Corpfin Capital to develop the company into an industry leader led by a talented, engaged management team,” said Jesús Torres, CEO of Prince Capital. “Kiwoko is exemplary of the opportunity for growth and investment in the Spanish retail sector, and we believe TA Associates’ guidance will further the company’s ability to compete with the large European market players.”

"We are very grateful to Corpfin and Prince for their trust and support during the last eight years, and are confident that TA’s support will allow us to expand Kiwoko’s leadership position, helping Spanish and Portuguese pet owners improve the lives of their pets,” said Javier Osa and Álvaro Gutiérrez, co-founders of Kiwoko.

Latham & Watkins served as legal counsel to TA Associates. Alemany, Escalona & De Fuentes served as legal advisor to Corpfin Capital and Prince Capital.

About TA Associates
TA Associates is one of the largest and most experienced global growth private equity firms. The firm has invested in more than 460 companies around the world and has raised $24 billion in capital. With offices in Boston, Menlo Park, London, Mumbai and Hong Kong, TA Associates leads buyouts and minority recapitalizations of profitable growth companies in the business services, consumer, financial services, healthcare and technology industries. More information about TA Associates can be found at www.ta.com.

About Corpfin Capital
Corpfin Capital is the longest established independent private equity firm in the Spanish market with more than 25 years of experience. Since its founding, Corpfin Capital has successfully managed c. €700 million with an investment strategy focused on the local and international expansion of Spanish SMEs across a wide variety of sectors. Corpfin Capital is currently investing Corpfin Capital Fund IV, from which it has already completed various acquisitions such as: Logiters (number two contract logistics company in Spain), El Fornet (fast growing regional coffee and bakery chain), Preving Group (build-up in employee health and safety compliance services), Secna (global producer of natural colorants for the food industry), and Arenal (fast growing hygiene, beauty and health specialty retailer).

About Prince Capital Partners
Prince Capital Partners is the first and only private venture capital company in Asturias. It was established in February 2008 with the vocation of making the necessary financial resources available to Spanish companies so that they can make the most of their potential for growth and expansion, prioritizing companies that are undergoing a process of business consolidation. Currently, Prince Capital is a shareholder in Azvase (a company offering services for the elderly), Coonic (the communication agencies and marketing online group), and Huni Hotel School (educational project focused on tourism). Prince is managed by Torsa Capital, SGEIC SA, an entity that has begun the fundraising of a new private equity fund and expects to have it operational by the end of the year.

Contact information

TA Associates
Marcia O’Carroll, 617-574-6796
mocarroll@ta.com
or
BackBay Communications
Stephen Fishleigh, +44-203-475-7552
stephen.fishleigh@backbaycommunications.com
or
Philip Nunes, 617-391-0792
phil.nunes@backbaycommunications.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00Pressemelding

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10Pressemelding

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13Pressemelding

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00Pressemelding

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41Pressemelding

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00Pressemelding

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i